Compare IQV & FTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IQV | FTS |
|---|---|---|
| Founded | 1982 | 1885 |
| Country | United States | Canada |
| Employees | 93000 | 9900 |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6B | 29.2B |
| IPO Year | 2013 | N/A |
| Metric | IQV | FTS |
|---|---|---|
| Price | $168.96 | $57.41 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 1 |
| Target Price | ★ $227.13 | $72.00 |
| AVG Volume (30 Days) | ★ 1.2M | 734.5K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 3.16% |
| EPS Growth | ★ 4.67 | N/A |
| EPS | ★ 7.84 | N/A |
| Revenue | ★ $9,739,000,000.00 | N/A |
| Revenue This Year | $6.78 | $11.05 |
| Revenue Next Year | $5.88 | $5.32 |
| P/E Ratio | ★ $22.03 | $22.72 |
| Revenue Growth | ★ 41.60 | N/A |
| 52 Week Low | $134.65 | $45.45 |
| 52 Week High | $247.05 | $58.78 |
| Indicator | IQV | FTS |
|---|---|---|
| Relative Strength Index (RSI) | 44.69 | 60.96 |
| Support Level | $159.42 | $56.05 |
| Resistance Level | $170.89 | $57.59 |
| Average True Range (ATR) | 6.19 | 0.90 |
| MACD | 1.31 | 0.11 |
| Stochastic Oscillator | 36.04 | 84.45 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Fortis owns and operates eight utility transmission and distribution subsidiaries in Canada and the United States, serving roughly 3.5 million electricity and gas customers. The company has smaller stakes in electricity generation and several Caribbean utilities. Subsidiary ITC operates electric transmission in seven US states, with more than 16,000 miles of high-voltage transmission lines in operation.